29 results about "Amnion" patented technology

The invention discloses a composite amnion for improving contracture after tissue repair and a preparation method of the composite amnion. The composite membrane comprises a recombinant humanized collagen nanofiber membrane located in the middle layer and human decellularized amniotic membranes attached to the two faces of the nanofiber membrane. The composite membrane is prepared by preparing a recombinant humanized collagen nanofiber membrane through an electrostatic spinning technology and pressing the recombinant humanized collagen nanofiber membrane and a human decellularized amniotic membrane. The composite membrane has excellent mechanical properties and biological activity. Animal experiment results show that the composite film can effectively inhibit capsule contracture induced by radiotherapy, and the comprehensive effect of the composite film is obviously superior to that of a single-component material in the aspects of inflammation resistance, fibrosis resistance, degradation speed delaying, capsule compliance improving and the like. The composition can be used for improving the capsule contracture of the breast prosthesis, especially the capsule contracture induced by radiotherapy.

This disclosure generally relates to methods of preparing a graft for wound healing. In some embodiments, the methods comprise obtaining a donor placenta and isolating tissue comprising amnion and / or chorion from the donor placenta. In other embodiments, the methods comprise washing the isolated tissue with a cleansing solution. Other embodiments, still, are directed toward applying a current to the isolated tissue and / or cleansing solution to produce the graft for wound healing.

The utility model relates to the technical field of cervical cerclage, in particular to a cervical cerclage support for cervical insufficiency, which comprises a protective ring, a push rod, first connecting blocks, a fixing rod, a silica gel pad and a second connecting block, the push rod is slidably connected in the protective ring, the first connecting blocks are connected at the upper end of the push rod at equal intervals, and the fixing rod is connected with the silica gel pad. Fixing rods are rotationally connected to the first connecting blocks, silica gel pads are jointly connected between the fixing rods, and second connecting blocks are rotationally connected to the fixing rods. The fixing rod and the silica gel pad are installed, due to the fact that the amniotic sac is protected by the silica gel pad, the silica gel pad can effectively isolate direct contact between a suturing instrument and the amniotic sac, the softness and the elasticity of the silica gel pad can adapt to the shape of the amniotic sac, comprehensive protection is provided, and through protection of the silica gel pad, the suturing instrument can be prevented from being damaged. A doctor can perform suture operation more trustingly, the safety and success rate of an operation are effectively improved, and the operation risk is reduced.

The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

This invention discloses an amniotic membrane mechanical tensile loading measurement device, relating to the field of membrane biomaterial research technology. It includes a fixed frame, a first clamping block assembly, a second clamping block assembly, a driving mechanism, and a monitoring device. The first and / or second clamping block assemblies are slidably disposed within the fixed frame, and the driving mechanism is fixedly disposed on the fixed frame. The driving mechanism can drive the first and second clamping block assemblies to move closer or further apart. Each clamping block assembly includes an upper clamping block, a lower clamping block, and a clamping locking mechanism. One of the upper and lower clamping blocks has a meshing groove, and the other has a meshing tooth. The two ends of the amniotic membrane are respectively fixed to the two clamping block assemblies. The clamping locking mechanism is a magnetic suction element. A microscope can be aligned with the amniotic membrane between the first and second clamping block assemblies. The monitoring device is used to monitor the operating parameters of the driving mechanism. This invention enables real-time in-situ observation in conjunction with a microscope and provides a stable clamping effect.

The invention relates generally to the fields of biology and life sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in morselized amniotic membrane tissue and morselized umbilical cord tissue preparations.

The present invention relates to functionally improved epithelial stem cells. The epithelial stem cells with improved functionality by a method of the present invention are prepared without genetic modification, thus being less likely to cause side effects due to DNA delivery / modification, are derived from the amniotic membrane in which no tissue-compatible antigen (factor) is expressed, thus having no rejection, and exhibit improved cell migration and would healing effects due to the improved functionality. Therefore, the epithelial stem cells can be used for the regeneration of various tissues, including the cornea, amniotic membrane, skin, and the like, and particularly can be used for the prevention or treatment of premature rupture of the amniotic membrane.

Compositions comprising perforated, unseparated amnion / chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

The present invention provides a birth tissue derived implant for treating a subject. The birth tissue derived implant comprises a birth tissue and an agent exogenous to the birth tissue. The birth tissue is isolated from an amniotic sac, an umbilical cord or a placental plate. A method is also provided for repairing a defective tissue in a subject. The repair method comprises delivering the birth tissue derived implant to a surface of the defective tissue in the subject. The defective tissue may be an ocular membrane, a synovium, tendon, ligament, nerve, a cartilage or a bone. A method is further provided for preparing the birth tissue derived implant. The preparation method may comprise devitalizing or decellularizing a birth tissue from an amniotic sac, an umbilical cord or a placental plate, and adding an agent to the devitalized or decellularized birth tissue.

The invention relates to the technical field of stem cells, in particular to a preparation method of human placenta amnion pluripotent stem cells. The method specifically comprises the following steps: S1, tissue pretreatment and physical pre-layering; s2, carrying out mechanical-enzymatic synergistic dynamic dissociation; s3, gradient purification and washing; s4, performing soft matrix phenotype maintenance culture; according to the method disclosed by the invention, the separation efficiency of amniotic epithelial cells is improved and the enzyme exposure load is reduced through synergistic enzymolysis of Dispase II and Trypsin in combination with weak shearing force generated by the magnetic beads. Meanwhile, SB431542 blocks a signal channel to prevent EMT, a GelMA soft matrix maintains cell phenotypes, and Percoll density gradient centrifugation is matched to improve cell purity.

A sterile micronized composition prepared from intact human placental tissue that is configured for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.

This present disclosure describes an amniotic membrane fetal tissue product with adhesive properties for use on an ocular surface to prevent or treat eye indications.

The invention relates to the technical field of stem cell engineering and anti-aging biology, in particular to a histone modification regulation method based on placenta amnion sub-totipotent stem cells and an anti-aging preparation thereof. The regulation and control method comprises the following steps: separating and purifying healthy full-month caesarean section placenta amniotic membrane tissues, carrying out composite enzymolysis and flow cytometry screening to obtain CD105 < + >, CD73 < + > and CD45 <-> stem cells, and primarily culturing the CD105 < + >, CD73 < + > and CD45 <-> stem cells; the method comprises the following steps: determining histone methyltransferase MLL3 and demethylase JMJD3 as target spots through ChIP-seq, and determining H3K4me3 and H3K27me3 as target modification sites; an MLL3 activator CM-272 with the final concentration of 15 [mu] M and a JMJD3 inhibitor GSK-J4 with the final concentration of 10 [mu] M form a composite regulator, and induction culture is performed for 84 h under the conditions of 37 DEG C and 5% CO2; and carrying out Western Blot verification and screening on the stem cells meeting the standard. According to the anti-aging preparation, regulated stem cells are used as active ingredients, a sodium alginate-gelatin (2: 1) composite carrier, 5% mannitol and 1% human serum albumin protective agent are used as auxiliary materials, and the injection with the pH of 7.2-7.4 is prepared. The method is accurate in regulation and control, and the preparation is remarkable in anti-aging effect and low in immunological rejection risk.

The utility model discloses a storage and taking device for a wet biological amnion. The storage and taking device comprises a protection tank and a storage box inserted into the protection tank, two height control assemblies are symmetrically installed on the left side and the right side of the protection tank, a temperature adjusting assembly used for temperature control is electrically connected into the protection tank, and clamping protection assemblies used in cooperation with the height control assemblies are slidably installed on the two sides of the temperature adjusting assembly. According to the wet biological amnion storage and taking device, the storage box and the protection tank are subjected to multiple sealing, the temperature is accurately controlled to be 2-8 DEG C through the temperature adjusting assembly, and the amnion storage time is prolonged; height control is matched with the clamping protection assembly, a ball screw is used for driving a sliding block to control a height adjusting block and an arc-shaped rotating plate, stable storage and taking are achieved, and transportation and operation shaking is reduced; the arc-shaped rotating plate and a rubber convex block of the temperature control base cooperate for damping, and the risk of vibration damage is reduced; a limiting window is matched with a light supplementing lamp to conveniently observe amniotic membrane conditions to adjust the environment.

Provided are a stem cell-derived gastruloid model, method for constructing same, and use thereof. The gastruloid model is constructed in vitro from human pluripotent stem cells, and simulated the biological events of early embryonic development and the key structures of the embryo to a certain extent, such as the development of primitive endoderm, the establishment of bilaminar germ disc, the appearance of the amniotic cavity and amniotic cells, and the appearance of the primitive streak and the like, which has been verified at both the protein level and the transcriptome level, and the key features of embryos from the peri-implantation period to the gastrula period could be well reproduced. This model can be induced in batches as a drug screening model for early embryos and environmental toxicants and the like, thereby providing safety testing for the use of drugs for certain clinical patients in early pregnancy and so on.

This invention discloses the application of MIF gene silencing in the preparation of drugs for treating premature rupture of membranes (PPROM), belonging to the fields of biomedicine and molecular biology. By collecting fetal membrane tissues from patients with PPROM and normal controls, this invention found that the expression level of MIF protein and the concentration of PGE2 were significantly increased in the PPROM group. Further investigation using siRNA technology to silence the MIF gene in human amniotic epithelial cells revealed that MIF silencing significantly reduced PGE2 levels. This invention is the first to demonstrate that MIF gene silencing can effectively treat PPROM by reducing PGE2 (inhibiting uterine contractions). This invention also provides a pharmaceutical composition containing MIF siRNA. This invention provides a novel molecular target and therapeutic strategy for the treatment of PPROM, with broad clinical application prospects.

This present disclosure describes an amniotic membrane fetal tissue product with adhesive properties for use on an ocular surface to prevent or treat eye indications.

The invention provides a precise nutrition regulation and control method for promoting intestinal development of young meat breeding chickens and application, belongs to the technical field of livestock and poultry breeding and production, and aims to solve the problem that hatching eggs laid by meat breeding chickens of 50 weeks old or above are insufficient in nutrition reserve, and L-methionine is injected through amniotic cavities when the meat breeding chickens are hatched to 17 embryonic ages. According to the method, the jejunum length, the jejunum weight and the ileum length (Plt: 0.05) of the 21-day-old offspring broiler chicken are remarkably increased, the expression of ileum proinflammatory factors (IL-8 and TNF-alpha) and apoptosis pathway genes (BAX, Caspase-3 and the like) is down-regulated, the expression of anti-apoptosis genes Bcl-2 is up-regulated, and the serum urea nitrogen level is reduced. Meanwhile, the daily average feed intake and the daily weight gain (Plt; 0.05) are improved. Through accurate intervention in the embryonic period, parent nutrition transfer limitation is broken through, the intestinal development and immune functions of offspring are improved, and an effective solution is provided for healthy breeding of offspring of elderly breeding hens.

The invention discloses a stem cell serum-free culture process optimized by artificial intelligence, which comprises the following steps: isolated culture of hAMSCs: firstly taking a healthy cesarean delivery amnion, cleaning bloodstain, removing chorion, cutting, soaking in PBS for 20 minutes, taking out, cutting into pieces, adding 0.25% trypsin, digesting at 37 DEG C for 30 minutes, cleaning after stopping digestion, adding 1mg / mL type IV collagenase, digesting at 37 DEG C for 1 hour, and culturing for 2-3 hours; the method comprises the following steps: adding the human amniotic mesenchymal stem cells into a culture medium containing 10% of FBS, 10 ng / mL of bFGF, 10 ng / mL of LEGF, 100 U / mL of mycillin and 2.5 [mu] g / mL of amphotericin B, and carrying out conventional culture under the culture conditions of 37 DEG C, 5% of CO2 and saturated humidity. The method has the following advantages: compared with the human amniotic mesenchymal stem cells cultured by fetal calf serum, the migration ability of the human amniotic mesenchymal stem cells cultured by fetal calf serum is enhanced.

Vesicoamniotic shunt deployment devices and related methods are generally described. A vesicoamniotic shunt may form a bypass connection between a fetal bladder and its amniotic sac to resume urine flow out of the bladder following a diagnosis of a lower urinary tract obstruction (LUTO). The deployment device may include a shaft, a trocar arranged coaxial to the shaft, and a handle at a distal end of the device. The device may include a trigger coupled to the shaft and the trocar, such that actuation of the trigger may linearly drive the shaft and the trocar, enabling highly controllable positioning of the shunt relative to the fetal bladder, reducing the risk of improper placement and dislodgement. In some embodiments, the surgeon may be able to deliver the vesicoamniotic shunt through a one-step trigger actuation, drastically reducing the complexity of the shunt placement procedure.

Compositions comprising perforated, unseparated amnion / chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital analysis is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.

The utility model relates to the technical field of medical instruments, in particular to an amniotic sac supporting anti-pricking device for cervical cerclage surgery, which comprises a base, a slider, a tray and a supporting rod, square sliding grooves for the slider to slide are formed in the side wall of the base in an annular array, and connecting grooves for connecting blocks to slide are formed in the tops of the sliding grooves; the tray is of a circular structure composed of a plurality of tray units, a driving mechanism is arranged at the bottom of the base to drive the sliding blocks to slide along the sliding grooves, and the top ends of the supporting rods are connected with the driving mechanism. The driving mechanism drives the sliding blocks to move outwards along the sliding grooves so that the connecting blocks and the tray units can be driven to move outwards, the size of the whole tray can be adjusted, the tray suitable for the sizes of different amniotic sacs can be adjusted according to the sizes of the different amniotic sacs to support the amniotic sacs, and trays with different diameters do not need to be prepared for supporting the amniotic sacs.

This disclosure generally relates to methods of preparing a graft for wound healing. In some embodiments, the methods comprise obtaining a donor placenta and isolating tissue comprising amnion and / or chorion from the donor placenta. In other embodiments, the methods comprise washing the isolated tissue with a cleansing solution. Other embodiments, still, are directed toward applying a current to the isolated tissue and / or cleansing solution to produce the graft for wound healing.

A fetal intrauterine positioning fixation device is configured for entering an amniotic cavity through a vaginal cervical fetal membrane access and / or abdominal wall uterine fetal membrane access to adjust and fix a fetal position in a maternal uterus. The fetal intrauterine positioning fixation device includes a manipulator, a mechanical arm and a surgical robot, the manipulator and mechanical arm can enter an amniotic cavity through a vaginal cervical fetal membrane channel or abdominal wall uterine fetal membrane channel, so that a doctor can control the manipulator and mechanical arm through the surgical robot or a handle to identify a fetus, adjust a fetal position and fix the fetus according to a preoperative planning, and monitor a fetal status in real time, expose a surgical treatment area, and create an operation space for implementing intrauterine fetal surgery.